TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17488411
Drug: GIK infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIK infusion (n = 14)
Study: 12228778
Drug: Type I
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type I antiarrhythmic agents (secondary prevention after myocardial infarction)
Study: 12228778
Drug: Alternative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative therapy (most often amiodarone)
Study: 8578181
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole daily for 6 months
Study: 8578181
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg omeprazole daily for 6 months
Study: 8578181
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole daily for 4-8 weeks
Study: 2189929
Drug: Five-drug antiemetic
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug antiemetic regimen (metoclopramide, dexamethasone, diazepam, diphenhydramine, thiethylperazine)
Study: 707580
Drug: Neither agent
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither agent (control group)
Study: 31238061
Drug: Standard exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard exercise (e.g., treadmill, cycling)
Study: 28784038
Drug: Pregabalin 50
Normalized name: pregabalin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 50 mg TDS for 3 days
Study: 28784038
Drug: Acetaminophen 500
Normalized name: acetaminophen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 500 mg/6 h for 3 days
Study: 23889722
Drug: Triple-combination treatment
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-combination treatment with olmesartan medoxomil (OM) 40 mg, amlodipine besylate (AML) 10 mg, and hydrochlorothiazide (HCTZ) 25 mg
Study: 22030597
Drug: Triple-combination treatment
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-combination treatment
Study: 22030597
Drug: Dual-combination treatments
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-combination treatments
Study: 15054353
Drug: Low-fat dietary
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat dietary intervention (less than 20% energy from fat, five or more fruit/vegetable and six or more grain servings daily)
Study: 11459901
Drug: 0.4 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg/day IVIg for 3 days
Study: 11459901
Drug: 0.4 g/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg/day IVIg for 6 days
Study: 9732070
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (ZDV + ddC or ddI)
Study: 9732070
Drug: Monotherapy (ZDV)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (ZDV)
Study: 9732070
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with BVL <10,000 HIV-1 RNA copies/ml
Study: 4051260
Drug: Papain (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papain (1 mg/mL)
Study: 29381568
Drug: Bupivacaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (10 mL) via ultrasound-guided LFC nerve block technique
Study: 22621316
Drug: Ongoing statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing statin + ezetimibe (simvastatin, atorvastatin or pravastatin + ezetimibe at doses of 20/10, 10/10 or 20/10 mg)
Study: 22621316
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the dose of ongoing statin (simvastatin 40 mg, atorvastatin 20 mg or pravastatin 40 mg)
Study: 19683989
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion initiated 5 days before surgery
Study: 19683989
Drug: Diltiazem infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem infusion before removing the RA
Study: 17603846
Drug: 10(6.7) focus‐forming
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(6.7) focus‐forming units of the attenuated RIX4414 human rotavirus vaccine
Study: 11524061
Drug: Felodipine-based regimen
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine-based regimen with additional antihypertensive drugs as needed
Study: 8596135
Drug: rh‐GM‐CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh‐GM‐CSF (5 micrograms/kg s.c. daily for 7 days)
Study: 2198807
Drug: Trivalent virus
Normalized name: Influenza Trivalent Virus Vaccine (Types A and B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent virus vaccine (measles AIK‐C strain, mumps Hoshino strain, rubella Takahashi strain)
Study: 2198807
Drug: Monovalent measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent measles vaccine (AIK‐C strain)
Study: 2198807
Drug: Monovalent mumps
Normalized name: mumps virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent mumps vaccine (Hoshino strain)
Study: 7234826
Drug: Naproxen (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (750 mg/day)
Study: 31184922
Drug: mDiab app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: mDiab app with weekly coach calls for 12 weeks
Study: 15331528
Drug: Insulin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.1 mU/kg body wt as bolus)
Study: 11546713
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg x kg(‐1) urapidil
Study: 11546713
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg x kg(‐1) urapidil
Study: 11546713
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg x kg(‐1) urapidil
Study: 9100580
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g glucose (Study 1)
Study: 9100580
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g glucose (Study 2)
Study: 7794122
Drug: Warfarin (2-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (2-7 mg daily)
Study: 2968309
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor (ANF) infusion (125 ng/kg bolus followed by a 30-minute infusion at 25 ng/kg/min)
Study: 26446709
Drug: Schema therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema therapy (ST)
Study: 29958220
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 µg/kg IV bolus in 10 minutes, followed by 0.5-1.0 µg/kg/h)
Study: 29958220
Drug: Remifentanil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.5 µg/kg IV bolus in 10 minutes, followed by 0.05-0.25 µg/kg/min)
Study: 28370407
Drug: BPS804 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPS804 (5, 10, and 20 mg/kg, three escalating doses each separated by 2 weeks)
Study: 19453322
Drug: i-gel supraglottic
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel supraglottic airway
Study: 17078446
Drug: Acupuncture; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture; specific dosage and duration not mentioned.
Study: 15154919
Drug: Root canal
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root canal treatment with one of three sealers chosen at random
Study: 11316108
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol 2.5 mg with ipratropium 0.5 mg and placebo inhalers (MDI) with spacer
Study: 11316108
Drug: Placebo nebules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nebules and inhaled salbutamol 400 microg with ipratropium 80 microg via MDI with spacer
Study: 11316108
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 400 microg with ipratropium 80 microg via MDI with spacer
Study: 8513853
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg b.i.d. isradipine
Study: 8513853
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of diclofenac and isradipine
Study: 24189569
Drug: self-help version
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: self-help version of cognitive behavioral therapy (shCBT)
Study: 21393063
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 1.5 g/day for 24 months
Study: 17194233
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg.kg(‐1))
Study: 12707479
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy plus routine care
Study: 11028832
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg tropisetron
Study: 2056905
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate (CC) 7.0 mg of anhydrous caffeine.kg‐1 body weight
Study: 7171533
Drug: High-methoxyl pectin
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-methoxyl pectin (15 g)
Study: 7171533
Drug: Low-methoxyl pectin
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-methoxyl pectin (15 g)
Study: 28010246
Drug: Monovalent rAT
Normalized name: rat skin extract
DrugBank: Rattus norvegicus skin (DB10608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent rAT or rLukS-PV dosages of 10, 25, 50, and 100 μg; bivalent rAT:rLukS dosages of 10:10, 25:25, and 50:50 μg; alum or saline placebo
Study: 28010246
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg monovalent or bivalent rAT and rLukS-PV dose
Study: 28010246
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of the vaccine
Study: 24508897
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of tenofovir alafenamide
Study: 24508897
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of tenofovir alafenamide
Study: 24508897
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of tenofovir disoproxil fumarate
Study: 15042669
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (paclitaxel followed by combined 5-fluorouracil, doxorubicin, and cyclophosphamide)
Study: 11180038
Drug: Everolimus 0.5
Normalized name: everolimus 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone
Study: 9621991
Drug: Antenatal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal corticosteroid therapy (ACT) with dexamethasone
Study: 9621991
Drug: Non-ACT group
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ACT group (no antenatal corticosteroid therapy)
Study: 9621991
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment of the mother
Study: 9621991
Drug: Tocolytic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocolytic treatment of the mother
Study: 3357663
Drug: Intraumbilical oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraumbilical oxytocin (10 U diluted to 20 mL in normal saline)
Study: 29102514
Drug: omalizumab 300
Normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: omalizumab 300 mg
Study: 27911016
Drug: omalizumab (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: omalizumab (75, 150 or 300 mg)
Study: 19090310
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of local anesthetic into the LITA tube
Study: 12818462
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose hormone replacement therapy (LD‐HRT) with conjugated equine estrogens (CEE; 0.3 mg) and different progestins (2.5 mg medroxyprogesterone acetate, 5 mg dydrogesterone, 2.5 mg nomegestrol)
Study: 10969300
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg/kg) administered 5 min before surgery
Study: 10969300
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg/kg) administered 10 min before surgery
Study: 10969300
Drug: Midazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5 mg/kg) administered 20 min before surgery
Study: 10969300
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 15 min before surgery
Study: 14621765
Drug: BT 563
Normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT 563 (new monoclonal IL-2R antibody)
Study: 26355978
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac (0.5 mg/kg) and acetaminophen (15 mg/kg)
Study: 26355978
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (10 mg/kg) and acetaminophen (15 mg/kg)
Study: 26355978
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen and acetaminophen
Study: 8769685
Drug: Pravastatin sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin sodium (10-15 mg/day for an average of 10.2 weeks)
Study: 8769685
Drug: Simvastatin (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (5-10 mg/day for an average of 13.9 weeks)
Study: 4073085
Drug: Ticarcillin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin plus clavulanic acid (3 g every four hours)
Study: 4073085
Drug: Clindamycin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin plus gentamicin (600 mg every six hours plus 3 to 5 mg/kg per day)
Study: 30415816
Drug: Ixekizumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab (80 mg/2 weeks after 160-mg initial dose)
Study: 26488229
Drug: 25 mL
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL hybrid palm oil daily for 3 months
Study: 26488229
Drug: 25 mL
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mL extra virgin olive oil daily for 3 months
Study: 24536039
Drug: Barberry (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barberry (3 capsules daily for 6 weeks)
Study: 24536039
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 capsules daily for 6 weeks)
Study: 22821620
Drug: Epinephrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (10 μg)
Study: 31044424
Drug: Phenylephrine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (100 μg)
Study: 20051221
Drug: Armodafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (200 mg once daily)
Study: 12630074
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone and somatomedins
Study: 7491886
Drug: Low-fat milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat milk (1.4 g Ca/d)
Study: 7491886
Drug: Fermented low-fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented low-fat milk (1.4 g Ca/d)
Study: 7491886
Drug: Soft drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft drink (0.16 g Ca/d)
Study: 30699971
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g freeze-dried blueberry powder
Study: 23551992
Drug: Partially hydrolysed
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolysed guar gum (PHGG), 10 g/d
Study: 17870123
Drug: Alarm treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alarm treatment (controls, group E)
Study: 12027843
Drug: Bain system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bain system + ACD with fresh gas flow 4.4‐6.4 l/min
Study: 12027843
Drug: Low flow
Normalized name: high mallow flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flow circle system with 1.5 l/min fresh gas flow
Study: 7589007
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (Tissucol, 5 ml of 500 IU thrombin) applied in the area of axillary dissection
Study: 7589007
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (Tissucol, 5 ml of 500 IU thrombin)
Study: 1425713
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg/12 h)
Study: 21502621
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg/12 h)
Study: 21502621
Drug: Gatifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin (400 mg/24 h)
Study: 21502621
Drug: Standard antituberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antituberculosis treatment alone (Control)
Study: 15294406
Drug: Previously prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previously prepared saline solutions
Study: 15294406
Drug: Saline solutions
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solutions exposed for 24, 48, or 72 hours
Study: 10395855
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccines (ACVs) - full strength, one-third strength, one-tenth strength
Study: 10395855
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccines (ACVs)
Study: 29145771
Drug: Simvastatin/chitosan gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin/chitosan gel (10 mg/mL) applied three times/day for 7 days
Study: 29145771
Drug: Simvastatin suspension
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin suspension
Study: 29145771
Drug: Petroleum gel
Normalized name: Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petroleum gel
Study: 23113482
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg intravenous infusion at baseline and 12 months)
Study: 20166859
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone patch (TTP, 300 microg/day)
Study: 12122534
Drug: Insufflation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insufflation of 10 ml/kg air into the stomach
Study: 8703663
Drug: rilmenidine 1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilmenidine 1-2 mg day-1
Study: 8703663
Drug: atenolol 50-100
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50-100 mg day-1
Study: 19954718
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride (60 mg/day, three times per week) for 1 year
Study: 17300851
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m2) plus Vinorelbine (25 mg/m2) bi-weekly
Study: 15167676
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg until the day before surgery)
Study: 15167676
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no aspirin or discontinued >5 days before surgery)
Study: 11316974
Drug: 375 mg/day
Normalized name: estradiol 0.0375 MG/DayTransdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated on the day of leuprorelin injection)
Study: 11316974
Drug: 375 mg/day
Normalized name: estradiol 0.0375 MG/DayTransdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated 1 week before leuprorelin injection)
Study: 11316974
Drug: 375 mg/day
Normalized name: estradiol 0.0375 MG/DayTransdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated 2 weeks before leuprorelin injection)
Study: 11316974
Drug: 375 mg/day
Normalized name: estradiol 0.0375 MG/DayTransdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg/day of orally administered flutamide combined with leuprorelin (initiated 4 weeks before leuprorelin injection)
Study: 11316974
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 3.75 mg leuprorelin acetate depot alone
Study: 7943592
Drug: No octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: No octreotide treatment (21 patients)
Study: 3581491
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg betahistine
Study: 26916927
Drug: Standardized physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized physical therapy exercise intervention
Study: 8368552
Drug: Nalbuphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (5 mg)
Study: 18201935
Drug: Morphine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (4 mg)
Study: 15734854
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg daily for 12 weeks)
Study: 12551868
Drug: abciximab (24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: abciximab (24-hour infusion)